AGEN Stock Overview
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Agenus Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.58 |
52 Week High | US$2.13 |
52 Week Low | US$0.48 |
Beta | 1.27 |
1 Month Change | -25.43% |
3 Month Change | -29.94% |
1 Year Change | -60.00% |
3 Year Change | -79.79% |
5 Year Change | -80.14% |
Change since IPO | -99.84% |
Recent News & Updates
Recent updates
Agenus: 2024 May Finally Be The Year For A Major Turnaround
Jan 18Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet
Dec 22News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
Nov 09A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)
Oct 04Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts
May 10VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma
Oct 12Agenus New Trials Set It Up For The Long Haul
Sep 27Agenus: It's Always Tomorrow
Sep 16Agenus GAAP EPS of -$0.17, revenue of $20.93M
Aug 09Agenus: Successfully Pulled Itself Away From Disaster
Jul 04Agenus: Not Quite Enough
Apr 19Auditors Have Doubts About Agenus (NASDAQ:AGEN)
Mar 06Agenus: Making Another Effort With The FDA
Jan 25Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains
Aug 25Agenus Multiple Value-Adding Events Ahead
Aug 18Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts
Aug 11FDA accepts Agenus' balstilimab BLA under "priority review" status
Jun 17Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy
May 26Agenus shares fall after Q1 topline miss
May 06Is Agenus Inc. (NASDAQ:AGEN) Popular Amongst Institutions?
Feb 15Shareholder Returns
AGEN | US Biotechs | US Market | |
---|---|---|---|
7D | 3.2% | 0.9% | 0.2% |
1Y | -60.0% | 11.0% | 28.1% |
Return vs Industry: AGEN underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: AGEN underperformed the US Market which returned 28.8% over the past year.
Price Volatility
AGEN volatility | |
---|---|
AGEN Average Weekly Movement | 15.1% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AGEN's share price has been volatile over the past 3 months.
Volatility Over Time: AGEN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 389 | Garo Armen | https://www.agenusbio.com |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
Agenus Inc. Fundamentals Summary
AGEN fundamental statistics | |
---|---|
Market cap | US$233.09m |
Earnings (TTM) | -US$245.97m |
Revenue (TTM) | US$156.31m |
1.6x
P/S Ratio-1.0x
P/E RatioIs AGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AGEN income statement (TTM) | |
---|---|
Revenue | US$156.31m |
Cost of Revenue | US$237.68m |
Gross Profit | -US$81.37m |
Other Expenses | US$164.61m |
Earnings | -US$245.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.59 |
Gross Margin | -52.05% |
Net Profit Margin | -157.36% |
Debt/Equity Ratio | -8.7% |
How did AGEN perform over the long term?
See historical performance and comparison